| 10894040 |
S1P modulating agents |
Jermaine Thomas, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell +2 more |
2021-01-19 |
$620,640,000 |
| 10435467 |
LINGO-1 antagonists and uses for treatment of demyelinating disorders |
Diego Cadavid |
2019-10-08 |
$181,372,000 |
| 10406144 |
SIP modulating agents |
Jermaine Thomas, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell +2 more |
2019-09-10 |
$383,447,000 |
| 10034869 |
S1P modulating agents |
Jermaine Thomas, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell +2 more |
2018-07-31 |
$178,334,000 |
| 10017506 |
ATX modulating agents |
Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Hairuo Peng, Zhaohui Shao +5 more |
2018-07-10 |
$486,265,000 |
| 9944666 |
Compounds that are S1P modulating agents and/or ATX modulating agents |
Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Hairuo Peng, Zhaohui Shao +4 more |
2018-04-17 |
$104,057,000 |
| 9808449 |
S1P modulating agents |
Jermaine Thomas, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell +2 more |
2017-11-07 |
$179,669,000 |
| 9796780 |
LINGO-2 antagonists for treatment of conditions involving motor neurons |
R. Blake Pepinsky |
2017-10-24 |
$333,689,000 |
| 9745375 |
Compositions comprising antibodies to LINGO or fragments thereof |
R. Blake Pepinsky, Christilyn Graff |
2017-08-29 |
$196,329,000 |
| 9555050 |
ATX modulating agents |
Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Zhaohui Shao, Lihong Sun +4 more |
2017-01-31 |
$458,474,000 |
| 9550798 |
Compounds that are S1P modulating agents and/or ATX modulating agents |
Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Hairuo Peng, Zhaohui Shao +4 more |
2017-01-24 |
$436,637,000 |
| 9522889 |
ATX modulating agents |
Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Hairuo Peng, Zhaohui Shao +5 more |
2016-12-20 |
$230,911,000 |
| 9340527 |
S1P modulating agents |
Jermaine Thomas, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell +2 more |
2016-05-17 |
$475,130,000 |
| 9107884 |
Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation |
Alain Chedotal, Frederic Bernard |
2015-08-18 |
$331,249,000 |
| 9066984 |
Sp35 antibodies and uses thereof |
R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff |
2015-06-30 |
$350,115,000 |
| 9068992 |
Screening methods for identifying Sp35 antagonists |
R. Blake Pepinsky, John McCoy |
2015-06-30 |
$350,115,000 |
| 8932821 |
NOGO receptor binding protein |
John McCoy, R. Blake Pepinsky, Daniel H.S. Lee |
2015-01-13 |
|
| 8894999 |
Use of DR6 and p75 antagonists to promote survival of cells of the nervous system |
Kenneth Rhodes, R. Blake Pepinsky |
2014-11-25 |
|
| 8765662 |
NOGO receptor binding protein |
John McCoy, R. Blake Pepinsky, Daniel H.S. Lee |
2014-07-01 |
|
| 8642040 |
Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists |
Vincent Jung |
2014-02-04 |
|
| 8609407 |
Sp35 antibodies and uses thereof |
R. Blake Pepinsky, Zhaohui Shao, Ellen Garber, Steven D. Miklasz, Christilyn Graff |
2013-12-17 |
|
| 8551476 |
SP35 antibodies and uses thereof |
R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff |
2013-10-08 |
|
| 8501178 |
Use of DR6 and p75 antagonists to promote survival of cells of the nervous system |
Kenneth Rhodes, R. Blake Pepinsky |
2013-08-06 |
|
| 8486893 |
Treatment of conditions involving demyelination |
R. Blake Pepinsky, John McCoy |
2013-07-16 |
|
| 8425910 |
Composition comprising antibodies to LINGO or fragments thereof |
R. Blake Pepinsky, Christilyn Graff |
2013-04-23 |
|